Navco Pharmaceuticals (TSXV:NAV) Net Income From Continuing Operations : C$-0.05 Mil (TTM As of Mar. 2023)

View and export this data going back to 2018. Start your Free Trial

What is Navco Pharmaceuticals Net Income From Continuing Operations?

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. Navco Pharmaceuticals's net income from continuing operations for the three months ended in Mar. 2023 was C$0.01 Mil. Its net income from continuing operations for the trailing twelve months (TTM) ended in Mar. 2023 was C$-0.05 Mil.

Navco Pharmaceuticals Net Income From Continuing Operations Historical Data

The historical data trend for Navco Pharmaceuticals's Net Income From Continuing Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Navco Pharmaceuticals Net Income From Continuing Operations Chart

Navco Pharmaceuticals Annual Data

Trend

Jun18

Jun19

Jun20

Jun21

Net Income From Continuing Operations

-0.19

-0.05

-0.07

Navco Pharmaceuticals Quarterly Data
	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23
Net Income From Continuing Operations	Get a 7-Day Free Trial														-0.01	-0.05	-	-0.01	0.01

Navco Pharmaceuticals Net Income From Continuing Operations Calculation

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Net Income From Continuing Operations for the trailing twelve months (TTM) ended in Mar. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-0.05 Mil.

Navco Pharmaceuticals (TSXV:NAV) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Navco Pharmaceuticals Inc (TSXV:NAV) » Definitions » Net Income From Continuing Operations

Comparable Companies

Traded in Other Exchanges

N/A

Address

1055 West Georgia Street, Suite 1500, Vancouver, BC, CAN, V6E 4N7

Website

Navco Pharmaceuticals Inc uses of nanotechnology to develop and commercialize novel products to protect against viruses, bacteria, and infectious diseases. The company's pipeline of applications is tailored to defend against pathogens utilizing new methods of action to capitalize on unmet product needs using natural & known compounds, nanoparticles, and no chemicals with a high degree of efficacy. Its target markets include human health & personal skin care, household & institutional products, and veterinary health.